# Kimberly-Clark account plan

> Kimberly-Clark makes Huggies, Kleenex, Scott and Depend, and acquired Kenvue in November 2026; FY2025 net sales were $16.4 billion.

## At a glance

Kimberly-Clark, founded in 1872 and headquartered in the Dallas, Texas area, makes personal care and tissue products from fibers, nonwovens and absorbent materials under brands including Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend and Pull-Ups, sold in more than 175 countries and territories. FY2025 continuing-operations net sales were $16.4 billion (-2.1%), operating profit $2.4 billion and adjusted EPS $6.12. It had approximately 36,000 employees and 74 production facilities in 30 countries at end-2025; Walmart represented approximately 16% of net sales. On November 2, 2026 it completed the acquisition of Kenvue (Listerine, Neutrogena, Tylenol), after placing its international tissue and professional business in a joint venture with Suzano on July 1, 2026.

## Business units

- **North America** (about 65% of FY2025 continuing net sales (computed; $10,753m)): Diapers, pants, wipes, feminine and incontinence care, tissue, towels and professional washroom products under Huggies, Pull-Ups, Kotex, Poise, Depend, Kleenex, Scott, Cottonelle, Viva and WypAll. FY2025 operating profit was $2,553m; Q3 2026 sales rose 0.9% to $2,738m with operating profit $657m (+2.7%). Led by John Carmichael, President, North America since September 2025.
- **International Personal Care** (about 35% of FY2025 continuing net sales (computed; $5,694m)): Baby & Child Care, Adult Care and Feminine Care outside North America, with key markets in China, Indonesia, Australia, South Korea and Brazil. FY2025 operating profit was $796m; in Q3 2026 sales fell 2.8% and operating profit 32.7% to $144m after a social media disruption in China. Led by Katy Chen since October 2024.
- **Arbex Joint Venture (former IFP, 49%)** (IFP net sales $3,254m in 2025, reported as discontinued): The international family care and professional business, contributed to a joint venture with Suzano that closed July 1, 2026; Suzano paid approximately $1.3 billion for 51%. Kimberly-Clark keeps 49% plus brand licences, supply agreements and transition services.
- **Kenvue**: Consumer health brands acquired on November 2, 2026, including Listerine, Neutrogena, Tylenol and Johnson's, with 10 billion-dollar brands. Kenvue brings a multibillion-dollar Western European business and presence in 3.1 million stores in India. COO Russ Torres leads the integration.
- **Equity companies** ($196m share of net income in 2025): Mainly Kimberly-Clark de Mexico, 47.9% owned and publicly traded in Mexico.

## Strategic priorities

- **Kenvue integration and synergies**: Targeted $2.1 billion of annual synergies net of reinvestment, including about $1.9 billion of cost synergies within three years, phased about 40%/40%/20%; the Kenvue Integration Program carries approximately $3.1 billion of pre-tax charges through 2029.
- **Powering Care strategy**: Three pillars: pioneering innovation through proprietary technology, an optimized margin structure across the good, better, best ladder, and an organization wired for growth. Innovation drove 78% of 2025 volume and mix growth.
- **Productivity and supply chain**: The 2024 Transformation Initiative targets $3.0 billion of gross productivity and $200m of SG&A savings at approximately $1.5 billion of cost, now extended to end-2028; $2 billion is being invested in North America manufacturing, including a Warren, Ohio plant and a Beech Island, South Carolina distribution center.
- **Margin targets**: Adjusted gross margin of at least 40% and adjusted operating margin of at least 18-20% before the end of the decade, with leverage below 2.0x net debt-to-EBITDA and a single-A rating.
- **Pure-play personal care and health**: Pivot to higher-growth, higher-margin categories: PPE sold, about $650 million of private label exited, IFP moved to the Suzano joint venture, and Kenvue added.

## Latest results

In Q3 2026 net sales were $4,134m (-0.4%), with organic sales -1.3% including an approximately 270 basis point headwind from the China social media disruption. Operating profit fell to $516m from $621m, including $106m of Kenvue acquisition costs; adjusted operating profit was $677m (-0.9%) and adjusted EPS from continuing operations $1.70 (+17.2%) on lower interest and tax. North America grew sales 0.9% while International Personal Care fell 2.8%. Nine-month net sales were $12,486m (+1.0%). The 2026 standalone outlook was reaffirmed: adjusted operating profit up mid-single digits and adjusted EPS from continuing operations up high single digits at constant currency.

## Investments and deals

- **Kenvue acquisition**: Completed November 2, 2026 for approximately $6.7 billion of cash and approximately 281.1 million Kimberly-Clark shares, funded partly by $4.9 billion of new senior notes.
- **Suzano joint venture**: The IFP joint venture closed July 1, 2026, with Suzano paying approximately $1.3 billion for 51% and a pre-tax gain of approximately $1.4 billion.
- **North America manufacturing**: $2 billion of investment in North America, including an advanced plant in Warren, Ohio and an automated distribution center at Beech Island, South Carolina.
- **Capital spending**: Capital spending was $1.1 billion in 2025, with approximately $1.3 billion expected in 2026.
- **Kenvue Integration Program**: Approximately $3.1 billion of charges through December 31, 2029, including supply chain network optimization (approximately $800m) and ERP and technology integration (approximately $600m).

## Challenges and risks

- **China diaper disruption**: False allegations about certain diaper brands spread on social media in China in Q2 2026, costing International Personal Care about 770 basis points of organic growth in Q3.
- **Input costs and tariffs**: About $100m of incremental tariff costs hit 2025, and the Middle East conflict is expected to add approximately $250m of input costs in 2026 before mitigation.
- **Integration and debt**: The Kenvue deal brings completion and integration risks, possible loss of customers or employees, and substantially higher indebtedness.
- **Private label and retailer concentration**: Private label pressure in baby and family care, growing retailer concentration and dependence on Walmart, at approximately 16% of net sales.
- **Birth-rate declines and litigation**: Falling birth rates in China, South Korea and the US pressure baby care volumes; Kenvue brings Tylenol and talc litigation, which management says due diligence assessed.

## What leadership says

> "The completion of our Kenvue transaction earlier this week marks a defining moment in the 154 year history of Kimberly-Clark." — Mike Hsu, Chairman and CEO, Q3 2026 earnings release, November 5, 2026

> "Our innovation pipeline has never been stronger." — Mike Hsu, Chairman and CEO, Q4 2025 earnings remarks, January 27, 2026

> "we are the best product and we're going to have the lowest cost." — Mike Hsu, Chairman and CEO, CNBC Mad Money interview, November 7, 2025

> "we still see generational value creation opportunity by putting these two companies together." — Russ Torres, President and COO, Q4 2025 earnings Q&A, January 27, 2026


## Where a supplier can help

- **ERP and systems integration**: Tied to the Kenvue Integration Program and its approximately $600m ERP and technology integration bucket: integration, data migration and change-management services.
- **Supply chain automation**: Tied to the productivity priority and the Warren, Ohio plant and Beech Island distribution center: automation, network optimization and manufacturing equipment suppliers.
- **G&A and procurement efficiency**: Tied to the cost synergies, about 40% expected from G&A overheads: procurement, shared services and real estate consolidation offerings.
- **Consumer trust and social listening in China**: Tied to the China social media disruption challenge: reputation monitoring and consumer communication tools address a demonstrated risk.
- **Input cost management**: Tied to tariffs and Middle East input-cost pressure: sourcing, hedging and materials-substitution services support margin targets.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Annual Report on Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/55785/000162828026007567/kmb-20251231.htm)

Annual report · 2026-02-12

- Kimberly-Clark (founded 1872, HQ Dallas, Texas) makes and markets products from natural or synthetic fibers using technologies in fibers, nonwovens and absorbency; brands such as Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend and Pull-Ups hold No. 1 or No. 2 positions in approximately 70 countries and are sold in more than 175 countries and territories.
- FY2025 continuing-operations net sales were $16.4 billion (-2.1%), with organic sales +1.7% driven by volume +2.5%; operating profit $2.4 billion (-12.9%), adjusted operating profit $2.7 billion, in line with 2024; adjusted EPS $6.12; diluted EPS from continuing operations $4.86.
- Two reportable segments after the IFP carve-out: North America ($10,753m sales, $2,553m operating profit) and International Personal Care ($5,694m sales, $796m operating profit); the International Family Care and Professional (IFP) business ($3,254m sales in 2025) is reported as discontinued operations.
- Portfolio pivot: IFP moves into a joint venture with Suzano (Suzano buys 51% for approximately $1.7 billion, K-C keeps 49%, closing expected mid-2026); PPE business sold in 2024 for $635m; US private label diaper business exited.
- Pending acquisition of Kenvue (signed November 2, 2025): 0.14625 K-C shares plus $3.50 cash per Kenvue share, approximately 280 million new shares and approximately $6.7 billion of cash; K-C holders to own approximately 54% and Kenvue holders approximately 46%; closing expected in the second half of 2026.
- Powering Care strategy and 2024 Transformation Initiative: three pillars (pioneering innovation, margin structure, organization wired for growth); $3.0 billion of gross productivity and $200m of SG&A savings targeted, total costs approximately $1.5 billion, workforce reductions of 4% to 5%.
- Walmart represented approximately 16% of net sales; approximately 36,000 employees; 74 production facilities in 30 countries; capex $1.1 billion in 2025, approximately $1.3 billion expected in 2026.
- Main risks: input costs and tariffs (approximately $100m of incremental tariff costs in 2025), private-label and retailer concentration, birth-rate declines in China, South Korea and the US, Russia exposure (1% to 2% of sales), and the Kenvue integration and the substantially higher debt it brings.

### [Quarterly Report on Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/55785/000162828026070754/kmb-20260930.htm)

Interim report · 2026-11-05

- Q3 2026 net sales $4,134m (-0.4%), organic -1.3% including an approximately 270 basis point headwind from the China social media disruption; nine-month net sales $12,486m (+1.0%), organic +0.3%.
- Q3 operating profit $516m (-16.9%) including $106m of Kenvue acquisition costs; adjusted operating profit $677m vs $683m; adjusted EPS from continuing operations $1.70 (+17.2%) on lower interest and tax.
- North America Q3 sales $2,738m (+0.9%) and operating profit $657m (+2.7%); International Personal Care Q3 sales $1,396m (-2.8%) and operating profit $144m (-32.7%), hit by the China diapers disruption.
- IFP joint venture with Suzano (Arbex Joint Venture) closed July 1, 2026: Suzano paid approximately $1.3 billion for 51%, K-C retains 49% (initial fair value approximately $1.2 billion); pre-tax gain of approximately $1.4 billion.
- Kenvue acquisition completed November 2, 2026: approximately $6.7 billion cash and approximately 281.1 million K-C shares; funded partly by $4.9 billion of new senior notes issued October 29, 2026.
- Kenvue Integration Program approved October 30, 2026: cumulative pre-tax charges of approximately $3.1 billion ($2.5 billion cash) through 2029, aimed at operating profit synergies by 2030.
- 2024 Transformation Initiative extended to end-2028 (cumulative charges $968m); Middle East conflict expected to add approximately $250m of input costs for the year before mitigation.

### [Kimberly-Clark Announces Third Quarter 2026 Results, Reaffirms 2026 Standalone Outlook (earnings release)](https://www.sec.gov/Archives/edgar/data/55785/000162828026070514/kmbq32026ex-991.htm)

Interim report · 2026-11-05

- Q3 2026 net sales $4.1 billion (-0.4%), organic -1.3%; adjusted operating profit $677 million (-0.9%); adjusted EPS from continuing operations $1.70 (+17.2%).
- The China social media disruption cost approximately 270 basis points of organic growth and approximately 530 basis points of adjusted operating profit in the quarter; North American retailer inventory movements also weighed.
- North America: sales $2.7 billion (+0.9%), organic +0.4% on volume +2.0%, operating profit $657 million (+2.7%).
- International Personal Care: sales $1.4 billion (-2.8%), organic -4.6% (about 770 basis points from China), operating profit $144 million (-32.7%).
- 2026 standalone outlook reaffirmed: organic growth approximately 100 basis points below weighted category growth (approximately 1.7%), adjusted operating profit up mid-single digits and adjusted EPS from continuing operations up high single digits at constant currency.
- CEO Mike Hsu calls the Kenvue completion "a defining moment in the 154 year history of Kimberly-Clark"; the new company describes itself as "the preeminent global health and wellness leader" with brands including Huggies, Listerine, Neutrogena, Tylenol and Kleenex.
- Nine-month operating cash flow $2.4 billion, capex $1.0 billion, $1.3 billion returned through dividends; debt from continuing operations $6.5 billion.

### [Q4 2025 earnings: prepared remarks and Q&A excerpts (Mike Hsu, Russ Torres, Nelson Urdaneta)](https://www.sec.gov/Archives/edgar/data/55785/000110465926007049/tm262467d7_425.htm)

Executive talk · Mike Hsu, Chairman and Chief Executive Officer · 2026-01-27

- Hsu frames two years of Powering Care as a "Virtuous Cycle of growth": 2025 volume-led organic growth of approximately 2%, the eighth consecutive quarter of volume-plus-mix growth, and 78% of volume and mix growth from innovations launched in the last three years.
- Productivity: 6.2% of adjusted COGS in 2025 (7.2% in Q4); 50% of the 5-year gross productivity ambition delivered in two years; a $2 billion North America investment in a Warren, Ohio plant and a Beech Island, South Carolina distribution center.
- Kenvue: a $32 billion pure-play health and wellness leader with 10 billion-dollar brands; $2.1 billion of annual synergies net of reinvestment, including about $1.9 billion of cost synergies phased 40%/40%/20% over three years; COO Russ Torres leads the Integration Management Office.
- CFO Nelson Urdaneta: adjusted gross margin of at least 40% and adjusted operating margin of at least 18-20% targeted before the end of the decade; adjusted free cash flow of about $2 billion a year; leverage below 2.0x, single-A rating.
- 2026 outlook: organic growth in line to ahead of categories, adjusted operating profit up mid-to-high single digits, double-digit adjusted EPS growth from continuing operations, capex about $1.3 billion.
- Kenvue expected to cause no more than mid-single digit adjusted EPS dilution in 2027 and significant accretion in 2028.
- IPC: over 900 basis points of China diaper share gained in five years; Q4 IPC organic growth at mid-single-digit levels; Torres sees "very, very significant upside" in premium tiers internationally.

### [Morgan Stanley Global Consumer & Retail Conference fireside chat (Mike Hsu and Nelson Urdaneta)](https://www.sec.gov/Archives/edgar/data/55785/000110465925118183/tm2532701d1_425.htm)

Executive talk · Mike Hsu, Chairman and Chief Executive Officer · 2025-12-03

- Hsu presents Kenvue as a chance to build "the preeminent personal wellness leader", with a "crown jewel portfolio" and a "plug-and-play approach" learned at Kraft.
- Geographic complementarity: Kenvue has a multibillion-dollar business in Europe, where K-C will have almost none after the IFP spin, and is in 3.1 million of 5 million outlets in India; K-C de Mexico is a $3 billion business.
- CFO Urdaneta: $1.9 billion of cost synergies (about 12% of Kenvue sales) within three years, about 80% in the first two years; about $2.5 billion of costs to achieve; G&A about 40% and sales and marketing about 30% of savings.
- G&A gap: K-C runs at 11.5% to 12% of revenue, Kenvue closer to about 17%; non-working media 20% at K-C vs 40% at Kenvue.
- Tylenol and talc: due diligence with outside legal, regulatory and medical experts; Hsu says no scenario was found where liability exceeded synergy value creation.
- Base business: shift from 40% to 70% premium in North America over 10 years, but a "superior value proposition at every rung"; promotion is "not a growth driver for us"; Q4 organic growth expected around 2%.

### [CNBC Mad Money interview with Mike Hsu on the Kenvue acquisition](https://www.sec.gov/Archives/edgar/data/55785/000110465925108566/tm2530027d16_425.htm)

Executive talk · Mike Hsu, Chairman and Chief Executive Officer · 2025-11-07

- Hsu calls the Kenvue deal possibly "the second most important day in our company's history" and "the single largest shareholder value creation opportunity that I'll ever experience in my career", with "tens of billions" of value creation.
- Cost synergies: K-C runs "very, very lean", with overheads in the industry's top quartile; Kenvue's costs are "a little bit higher".
- Complementarity: Kenvue is in 3.1 million stores in India and has a multibillion-dollar Western European business, where K-C has almost no sales; K-C is strong in Indonesia, South Korea and Mexico.
- Channels: online sales account for 100% of K-C's North America growth this year; online shares are 700 basis points higher than offline.
- On Tylenol, Texas and UK talc claims: detailed due diligence with outside experts; "we would never put profits or sales ahead of the safety of our consumers."
- Strategy in a "barbell economy": premium innovation plus premium benefits cascaded into value tiers; mantra "we are the best product and we're going to have the lowest cost".

## Questions about Kimberly-Clark

### What does Kimberly-Clark do?

It makes personal care and tissue products such as Huggies, Kleenex, Scott, Kotex and Depend, and since November 2026 also Kenvue's consumer health brands such as Listerine, Neutrogena and Tylenol.

### What is Kimberly-Clark's revenue?

FY2025 continuing-operations net sales were $16.4 billion (-2.1%), with organic growth of 1.7%. Q3 2026 net sales were $4,134m.

### How many employees does Kimberly-Clark have?

Approximately 36,000 at the end of 2025, including the IFP business, before the Kenvue acquisition.

### Why did Kimberly-Clark buy Kenvue?

To build a health and wellness company with 10 billion-dollar brands, targeting $2.1 billion of annual synergies net of reinvestment and gaining scale in Western Europe and India.

### Who leads Kimberly-Clark?

Michael D. Hsu is Chairman and CEO, Russell Torres is President and COO, and Nelson Urdaneta is CFO.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
